66 related articles for article (PubMed ID: 31958257)
1. Real-life retrospective observational study to determine the prevalence and economic burden of severe asthma in Spain.
Sicras-Mainar A; Capel M; Navarro-Artieda R; Nuevo J; Orellana M; Resler G
J Med Econ; 2020 May; 23(5):492-500. PubMed ID: 31958257
[No Abstract] [Full Text] [Related]
2. Exacerbations, treatment patterns, utilization, and costs before and after initiating of benralizumab for the treatment of severe eosinophilic asthma.
Smith JL; Chung Y; Barron J; Barlows T; Nepal B; Carstens D
J Asthma; 2024 Jun; 61(6):520-531. PubMed ID: 38054593
[TBL] [Abstract][Full Text] [Related]
3. Epidemiological, clinical and economic burden of severe eosinophilic asthma in Taiwan: Results from a large tertiary care hospital.
Shantakumar S; Ho YF; Tuan LW; Lin TM; Hershko AY; Chen YH
Asian Pac J Allergy Immunol; 2023 Dec; 41(4):325-335. PubMed ID: 33274956
[TBL] [Abstract][Full Text] [Related]
4. Disease Burden of Mild Asthma: Findings from a Cross-Sectional Real-World Survey.
Ding B; Small M
Adv Ther; 2017 May; 34(5):1109-1127. PubMed ID: 28391549
[TBL] [Abstract][Full Text] [Related]
5. Economic burden of asthma: a systematic review.
Bahadori K; Doyle-Waters MM; Marra C; Lynd L; Alasaly K; Swiston J; FitzGerald JM
BMC Pulm Med; 2009 May; 9():24. PubMed ID: 19454036
[TBL] [Abstract][Full Text] [Related]
6. Predictive factors for moderate or severe exacerbations in asthma patients receiving outpatient care.
Gutiérrez FJÁ; Galván MF; Gallardo JFM; Mancera MB; Romero BR; Falcón AR
BMC Pulm Med; 2017 May; 17(1):77. PubMed ID: 28464895
[TBL] [Abstract][Full Text] [Related]
7. Prevalence, characteristics and management of frequently exacerbating asthma patients: an observational study in Sweden (PACEHR).
Janson C; Lisspers K; Ställberg B; Johansson G; Thuresson M; Telg G; Larsson K
Eur Respir J; 2018 Aug; 52(2):. PubMed ID: 29946008
[TBL] [Abstract][Full Text] [Related]
8. Social economic costs of COPD in Extremadura (Spain): an observational study.
Merino M; Villoro R; Hidalgo-Vega Á; Carmona C
Int J Chron Obstruct Pulmon Dis; 2018; 13():2501-2514. PubMed ID: 30174420
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness and resource use analysis of patients with asthma before and after treatment with mepolizumab in a real-life setting.
Domínguez-Ortega J; Laorden D; Vílchez-Sánchez F; Bañas-Conejero D; Quirce S
J Asthma; 2024 Jan; 61(1):39-47. PubMed ID: 37503953
[TBL] [Abstract][Full Text] [Related]
10. [Burden and management of severe asthma in Russia: results from international observational study].
Aisanov ZR; Kurbacheva OM; Emelyanov AV; Ignatova GL; Teichman L; Makarova JY; Fedosenko SV; Alfonso R; Elfishawy T
Ter Arkh; 2024 Apr; 96(3):212-217. PubMed ID: 38713034
[TBL] [Abstract][Full Text] [Related]
11. Identification and management of adults with asthma prone to exacerbations: can we do better?
Thomson NC; Chaudhuri R
BMC Pulm Med; 2008 Dec; 8():27. PubMed ID: 19116019
[TBL] [Abstract][Full Text] [Related]
12. Health care resource utilization and cost for asthma patients regularly treated with oral corticosteroids - a Swedish observational cohort study (PACEHR).
Janson C; Lisspers K; Ställberg B; Johansson G; Telg G; Thuresson M; Nordahl Christensen H; Larsson K
Respir Res; 2018 Sep; 19(1):168. PubMed ID: 30176850
[TBL] [Abstract][Full Text] [Related]
13. Risk factors for the development of bronchiectasis in patients with asthma.
Ma D; Cruz MJ; Ojanguren I; Romero-Mesones C; Varona-Porres D; Munoz X
Sci Rep; 2021 Nov; 11(1):22820. PubMed ID: 34819607
[TBL] [Abstract][Full Text] [Related]
14. Medical resource utilization and the associated costs of asthma in China: a 1-year retrospective study.
Yang X; Zhang T; Yang X; Jiang J; He Y; Wang P
BMC Pulm Med; 2023 Nov; 23(1):463. PubMed ID: 37993799
[TBL] [Abstract][Full Text] [Related]
15. Asthma outcomes: healthcare utilization and costs.
Akinbami LJ; Sullivan SD; Campbell JD; Grundmeier RW; Hartert TV; Lee TA; Smith RA
J Allergy Clin Immunol; 2012 Mar; 129(3 Suppl):S49-64. PubMed ID: 22386509
[TBL] [Abstract][Full Text] [Related]
16. Healthcare Resource Utilization and Cost-of-Illness in Systemic Light Chain (AL) Amyloidosis in Europe: Results From the Real-World, Retrospective EMN23 Study.
Jaccard A; Bridoux F; Roeloffzen W; Minnema MC; Bergantim R; Hájek R; João C; Cibeira MT; Palladini G; Schönland S; Merlini G; Milani P; Dimopoulos MA; Ravichandran S; Hegenbart U; Agis H; Gros B; Asra A; Magarotto V; Cheliotis G; Psarros G; Sonneveld P; Wechalekar A; Kastritis E
Clin Lymphoma Myeloma Leuk; 2024 May; 24(5):e205-e216. PubMed ID: 38453615
[TBL] [Abstract][Full Text] [Related]
17. Prevalence, T2 Biomarkers, and Cost of Severe Asthma in the Era of Biologics: The BRAVO-1 Study.
Domingo C; Sicras-Mainar A; Sicras-Navarro A; Sogo A; Mirapeix RM; Engroba C
J Investig Allergol Clin Immunol; 2024 Apr; 34(2):97-105. PubMed ID: 36420740
[TBL] [Abstract][Full Text] [Related]
18. Effect of asthma and asthma medication on the prognosis of patients with COVID-19.
Choi YJ; Park JY; Lee HS; Suh J; Song JY; Byun MK; Cho JH; Kim HJ; Lee JH; Park JW; Park HJ
Eur Respir J; 2021 Mar; 57(3):. PubMed ID: 32978309
[TBL] [Abstract][Full Text] [Related]
19. Geographic variation in disease burden among patients with severe persistent asthma in the United States.
Camargo CA; Rane PB; Beck AF; Wang Y; Chung Y; McGuiness CB; Llanos JP; Lindsley AW; Ambrose CS; Zhou Z; Chang HC; Wade RL
Ann Allergy Asthma Immunol; 2024 May; 132(5):602-609.e4. PubMed ID: 38141810
[TBL] [Abstract][Full Text] [Related]
20. Study of the Direct Costs of Asthma at a Healthcare Service Provider in Bogotá, Colombia.
Gil-Rojas Y; Lasalvia P; Sáenz V; Virgüez O; Peña MP; Castañeda-Cardona C; Laucho-Contreras ME; González AL; García-Nuncira CY; Rosselli D
Value Health Reg Issues; 2024 Jan; 39():6-13. PubMed ID: 37967491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
